Palonew Injection
Palonosetron
0.25 mg
Sun Pharmaceutical Industries Ltd.
| Pack size | |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price |
Indications
Palonew Injection is used for:
Chemotherapy-induced nausea and vomiting, Postoperative nausea and vomiting
Adult Dose
Intravenous
Prevention of Chemotherapy-induced Nausea & Vomiting
Adult: 0.25 mg IV as a single dose. To be given over 30 sec and 30 minutes before chemotherapy. Do not repeat within 7 days.
Prevention of Postoperative Nausea & Vomiting
Adult: 0.075 mg IV as a single dose immediately before induction of anaesthesia.
Hepatic impairment: Dose adjustment not necessary
Child Dose
Prevention of Postoperative Nausea & Vomiting
<18 years: Safety and efficacy not established
Prevention of Chemotherapy-induced Nausea & Vomiting
<1 month: Safety and efficacy not established
1 month to 17 years: 20 mcg/kg IV infused over 15 minutes x1, beginning 30 minutes before chemotherapy; not to exceed 1.5 mg/dose
Renal Dose
Renal impairment: Dose adjustment not necessary
Administration
Reconstitution: Physically and chemically stable at concentrations of 5 and 30 mcg/ml in glucose 5%, sodium chloride 0.9%, glucose 5% in lactated Ringer's for at least 48 hr at room temperature, exposed to light and for 14 days under refridgeration.
IV Administration
Flush IV line with NS before and after administration
CINV: give IVP evenly over 30 sec (adults) or 15 min (children)
PONV: IVP over 10 sec
Contra Indications
History of hypersensitivity.
Precautions
Patients with intestinal obstruction or ileus. Rapid inj may lead to temporary visual changes e.g. blurred vision. Patients who have or may develop prolonged QT intervals. Safety and efficacy not established in children <18 yr. Counsel patients who handle skilled tasks e.g. driving may be impaired.
Lactation: unknown, discontinue drug or do not nurse
Pregnancy-Lactation
Interactions
May have additive effect on prolonging QT with drugs e.g. moxifloxacin, erythromycin, antipsychotics and TCAs.
Adverse Effects
Side effects of Palonosetron :
1-10%
Prolonged QT interval (up to 5% ),Anxiety,Dizziness,Headache,Weakness,Constipation,Diarrhea,Prutitus,Hyperkalemia,LFT's increased
<1%
First degree atrioventricular block,Second degree atrioventricular block
Frequency Not Defined
Immune hypersensitivity reaction (very rare),Seizure
Mechanism of Action
Palonosetron is a selective 5-HT3 antagonist that is used in the prevention of acute and delayed emesis in emetogenic cancer chemotherapy regimens.
Note
Palonew 0.25 mg Injection manufactured by Sun Pharmaceutical Industries Ltd.. Its generic name is Palonosetron. Palonew is availble in Nepal.
Farmaco Nepal drug index information on Palonew Injection is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.